Oramed Pharmaceuticals Inc. (FRA:OJU1)

Germany flag Germany · Delayed Price · Currency is EUR
2.769
+0.019 (0.69%)
At close: Feb 20, 2026
Market Cap108.79M +28.4%
Revenue (ttm)1.70M
Net Income37.38M +882.1%
EPS0.88 +838.2%
Shares Outn/a
PE Ratio2.91
Forward PEn/a
Dividend0.22 (7.78%)
Ex-Dividend DateJan 16, 2026
Volume6,013
Average Volume949
Open2.665
Previous Close2.750
Day's Range2.665 - 2.769
52-Week Range1.744 - 3.121
Betan/a
RSI50.52
Earnings DateMar 27, 2026

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2002
Employees 4
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol OJU1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements